Technology
Illumina and the Center for Data-Driven Discovery in Biomedicine bring genomic data and scalable software to the fight against pediatric cancer and rare disease
Illumina (NASDAQ: ILMN) and the Center for Data-Driven Discovery in Biomedicine (D3b) today announced a data partnership to advance research in pediatric cancer and rare disease. Through cloud-based data platforms, the global research community can unify and analyze pediatric data within a single, scalable discovery environment, enabling real-time, cross-cohort analysis and accelerating translation to clinical care.
About this update from Illumina, Inc.
[{"type":"text","content":"Dataset will drive crucial insights to accelerate scientific discovery and ultimately improve pediatric patient care. ","length":117,"tagName":"p"},{"type":"text","content":"SAN DIEGO, April 14, 2026 /PRNewswire/ -- Illumina (NASDAQ: ILMN) and the Center for Data-Driven Discovery in Biomedicine (D3b) today announced a data partnership to advance research in pediatric cancer and rare disease. Through cloud-based data platforms, the global research community can unify and analyze pediatric data within a single, scalable discovery environment, enabling real-time, cross-cohort analysis and accelerating translation to clinical care.","length":461,"tagName":"p"},{"type":"text","content":"Through this initiative, D3b is analyzing 100,000 whole genomes from pediatric patients using Illumina software solutions. This is one of the largest unified genomic datasets ever assembled. D3b and Illumina are enabling discovery at a scale not previously possible, making the resulting insights available through the Gabriella Miller Kids First Data Resource Center (Kids First DRC). This data empowers researchers and clinicians to uncover the biological origins of rare disease and cancer and translate findings for pediatric precision medicine.","length":549,"tagName":"p"},{"type":"text","content":"Congenital conditions and cancers are a leading cause of death in children yet critical data are often siloed across institutions. Shared genomic data ecosystems enable researchers and clinicians to compare cases across large cohorts, validate diagnoses, and inform treatment strategies based on prior patient experiences.","length":322,"tagName":"p"},{"type":"text","content":""Genomic datasets like these give researchers powerful insight for precision medicine," said James Han, vice president of Bioinformatics at Illumina. "Through advances in data, software, and AI, we are moving toward a future where genomic insights drive faster research breakthroughs."","length":305,"tagName":"p"},{"type":"text","content":""We're excited to apply leading-edge software technology against some of the toughest challenges in pediatric cancer and congenital conditions," said Allison Heath, director of Data Technology and Innovation at D3b. "Our goal is to empower researchers to uncover new biological signals and to bring genomic insights ...